Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data

scientific article

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1185/030079907X210615
P698PubMed publication ID17588306

P50authorEric Q WuQ67190782
P2093author name stringLei Chen
Elaine Yang
Howard Birnbaum
Mary Cifaldi
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectrheumatoid arthritisQ187255
P304page(s)1749-1759
P577publication date2007-08-01
P1433published inCurrent Medical Research and OpinionQ5195063
P1476titleCost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data
P478volume23

Reverse relations

cites work (P2860)
Q46638150Applying Value-Based Insurance Design To High-Cost Health Services
Q36439036Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective
Q37992954Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis
Q43461275Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey
Q59822850Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical t
Q36274355Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis
Q34311262Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data
Q47188529Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-analysis.
Q38067449Similar biotherapeutic products: overview and reflections
Q35205411The economic burden of TNFα inhibitors and other biologic treatments in Norway
Q43194443The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients
Q84565204The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia
Q38062338Treatment costs of attention deficit hyperactivity disorder in Germany
Q36923598Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting
Q37000165Use of biologics in rheumatoid arthritis: current and emerging paradigms of care

Search more.